JP2021533199A5 - - Google Patents
Info
- Publication number
- JP2021533199A5 JP2021533199A5 JP2021529260A JP2021529260A JP2021533199A5 JP 2021533199 A5 JP2021533199 A5 JP 2021533199A5 JP 2021529260 A JP2021529260 A JP 2021529260A JP 2021529260 A JP2021529260 A JP 2021529260A JP 2021533199 A5 JP2021533199 A5 JP 2021533199A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- complex according
- transferrin receptor
- nucleotides
- dmpk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025004577A JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| JP2026063000A JP2026119090A (ja) | 2018-08-02 | 2026-04-07 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713914P | 2018-08-02 | 2018-08-02 | |
| US62/713,914 | 2018-08-02 | ||
| US201862779161P | 2018-12-13 | 2018-12-13 | |
| US62/779,161 | 2018-12-13 | ||
| US201962855761P | 2019-05-31 | 2019-05-31 | |
| US62/855,761 | 2019-05-31 | ||
| US201962858888P | 2019-06-07 | 2019-06-07 | |
| US62/858,888 | 2019-06-07 | ||
| US201962859672P | 2019-06-10 | 2019-06-10 | |
| US62/859,672 | 2019-06-10 | ||
| PCT/US2019/044987 WO2020028861A1 (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025004577A Division JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533199A JP2021533199A (ja) | 2021-12-02 |
| JP2021533199A5 true JP2021533199A5 (enExample) | 2022-08-09 |
| JP7705793B2 JP7705793B2 (ja) | 2025-07-10 |
Family
ID=69230803
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529260A Active JP7705793B2 (ja) | 2018-08-02 | 2019-08-02 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| JP2025004577A Active JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| JP2026063000A Pending JP2026119090A (ja) | 2018-08-02 | 2026-04-07 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025004577A Active JP7847681B2 (ja) | 2018-08-02 | 2025-01-14 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| JP2026063000A Pending JP2026119090A (ja) | 2018-08-02 | 2026-04-07 | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210308272A1 (enExample) |
| EP (1) | EP3829596A4 (enExample) |
| JP (3) | JP7705793B2 (enExample) |
| KR (1) | KR20210081323A (enExample) |
| CN (1) | CN112955154A (enExample) |
| AU (2) | AU2019314538B2 (enExample) |
| CA (1) | CA3108287A1 (enExample) |
| IL (2) | IL321905A (enExample) |
| MX (1) | MX2021001283A (enExample) |
| SG (1) | SG11202100925VA (enExample) |
| WO (1) | WO2020028861A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118638787A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2021142217A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Thereapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of milck1 |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| KR102927945B1 (ko) * | 2020-03-27 | 2026-02-23 | 어비디티 바이오사이언시스 인크. | 근이영양증의 치료용 조성물 및 방법 |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| MX2023000958A (es) * | 2020-07-23 | 2023-04-14 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de estos para el tratamiento de la distrofia miotonica. |
| CN116348139A (zh) * | 2020-07-23 | 2023-06-27 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| AU2021342155A1 (en) * | 2020-09-11 | 2023-04-13 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of DUX4, compositions thereof, and methods of use |
| KR20230117182A (ko) * | 2020-12-04 | 2023-08-07 | 다인 세라퓨틱스, 인크. | 항체-올리고뉴클레오티드 복합체 및 그의 용도 |
| AU2021414227A1 (en) * | 2020-12-31 | 2023-07-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| CA3226457A1 (en) * | 2021-07-30 | 2023-02-02 | Amy WALKER | Nanoparticles and peptides for the delivery of cargos to muscle cells |
| EP4124345A1 (en) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticles for muscle delivery |
| CA3230796A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| US11833221B2 (en) | 2021-09-01 | 2023-12-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds for reducing DMPK expression |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| US12527877B2 (en) | 2024-01-24 | 2026-01-20 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2691673A1 (en) * | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| ES2756326T3 (es) * | 2010-07-19 | 2020-04-27 | Ionis Pharmaceuticals Inc | Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK) |
| US9610362B2 (en) * | 2012-03-16 | 2017-04-04 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of DMPK |
| US10111962B2 (en) * | 2012-09-25 | 2018-10-30 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| HRP20180268T4 (hr) * | 2012-10-23 | 2026-03-27 | Synaffix B.V. | Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu |
| TW201536329A (zh) * | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| DK3473270T5 (da) * | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| KR20240172236A (ko) * | 2017-01-06 | 2024-12-09 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
-
2019
- 2019-08-02 CN CN201980062906.7A patent/CN112955154A/zh active Pending
- 2019-08-02 SG SG11202100925VA patent/SG11202100925VA/en unknown
- 2019-08-02 AU AU2019314538A patent/AU2019314538B2/en active Active
- 2019-08-02 KR KR1020217005992A patent/KR20210081323A/ko not_active Ceased
- 2019-08-02 IL IL321905A patent/IL321905A/en unknown
- 2019-08-02 US US17/264,905 patent/US20210308272A1/en not_active Abandoned
- 2019-08-02 EP EP19843799.8A patent/EP3829596A4/en active Pending
- 2019-08-02 JP JP2021529260A patent/JP7705793B2/ja active Active
- 2019-08-02 WO PCT/US2019/044987 patent/WO2020028861A1/en not_active Ceased
- 2019-08-02 IL IL280425A patent/IL280425B2/en unknown
- 2019-08-02 CA CA3108287A patent/CA3108287A1/en active Pending
- 2019-08-02 MX MX2021001283A patent/MX2021001283A/es unknown
-
2025
- 2025-01-14 JP JP2025004577A patent/JP7847681B2/ja active Active
- 2025-05-30 AU AU2025204039A patent/AU2025204039A1/en active Pending
-
2026
- 2026-04-07 JP JP2026063000A patent/JP2026119090A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533200A5 (enExample) | ||
| JP2021533197A5 (enExample) | ||
| JP2025067909A5 (enExample) | ||
| JP2021532832A5 (enExample) | ||
| JP2021533198A5 (enExample) | ||
| JP2023509793A5 (enExample) | ||
| JP2023512442A5 (enExample) | ||
| JP2023512441A5 (enExample) | ||
| JP2023510351A5 (enExample) | ||
| JP2023535078A5 (enExample) | ||
| JP2023535444A5 (enExample) | ||
| JP2023535073A5 (enExample) | ||
| JP2024525614A5 (enExample) | ||
| JP2022122928A5 (enExample) | ||
| JP2024501872A5 (enExample) | ||
| JP2023179497A (ja) | Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法 | |
| JP2020505330A5 (enExample) | ||
| JP2021532831A5 (enExample) | ||
| JP2023537798A5 (enExample) | ||
| IL317871A (en) | Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy | |
| JP2024527362A5 (enExample) | ||
| JP2024524222A5 (enExample) | ||
| JP2023527638A5 (enExample) | ||
| JP2024546436A5 (enExample) | ||
| CN112955154A (zh) | 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途 |